US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
SNDK
$1,704.16
▼-0.92%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
SNDK
$1,704.16
▼-0.92%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Cell BioEngines, Inc.
Cell BioEngines Announces Establishment of New R&D Facility to Further Advance Its Platform and Pipeline of Innovative Cell Therapies
January 21, 2025
From
Cell BioEngines, Inc.
Via
GlobeNewswire
Tickers
JLL
Cell BioEngines Secures an Additional $2 Million in Funding From SOSV and the Empire State Development’s New York Ventures
July 20, 2024
From
Cell BioEngines, Inc.
Via
GlobeNewswire
Cell BioEngines to Present at the 2024 BIO CEO & Investor Conference
February 08, 2024
From
Cell BioEngines, Inc.
Via
GlobeNewswire
SOSV-backed Biotech Firm Cell BioEngines Decides New York Is the Place to Be
January 13, 2024
From
Cell BioEngines, Inc.
Via
GlobeNewswire
Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program
December 29, 2023
From
Cell BioEngines, Inc.
Via
GlobeNewswire
Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology
September 07, 2023
From
Cell BioEngines, Inc.
Via
GlobeNewswire
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
January 25, 2023
From
Cell BioEngines, Inc.
Via
GlobeNewswire